Upper tract TCC bladder Cancer Malignant neoplasm of bladder
Conditions
Interventions
Intravesical instillation of Mitomycin-C post operatively versus no Mitomycin-C
Sponsors
Sussex NHS Research Consortium (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A new clinical diagnosis of a transitional cell tumour of the upper urinary tract above the intramural ureter 2. A negative cystoscopy for TCC bladder within one month of the nephroureterectomy 3. A nephroureterectomy that is planned to be performed in such a way that there is early distal ligation of the ureter prior to the mobilisation of the tumour. The intramural portion of the ureter may be resected prior to the open part of the operation, taken at the open operation with a cuff of bladder or everted at the end of the operation and resected endoscopically according to surgical preference. 4. Have a life expectancy of at least one year 5. Informed consent to participate (written and witnessed)
Exclusion criteria
Exclusion criteria: 1. The histology of the upper tract tumour does not confirm a transitional cell carcinoma 2. Stage N1 or M1 3. Had additional systemic chemotherapy or additional intravesical Mitomycin-C at follow up cystoscopies 4. Existing or previous transitional cell carcinoma of bladder 5. Children, pregnant women excluded 6. Life expectancy less than one year 7. Known sensitivity to Mitomycin-C
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To study the post surgical survival of these patients over five years. | — |
Primary
| Measure | Time frame |
|---|---|
| Incidence of tumour recurrence at 1 year post nephroureterectomy | — |
Countries
United Kingdom
Outcome results
None listed